source · text/markdown
source_2920647f0ed6427f
sha256 87d2d14b69f5df5b96a2e54f61a5b877a2c30c8badb11af9190c52f07d1d17db
by researka:v2 · 2026-07-04 09:37:43.750881+04:00
# Source literature boundary memo ## Research question Across retrieved source-level receipts for SGLT2 inhibitors, which endpoints show directionally favorable versus null/non-convergent signals, and what matched PICO remains untested? ## Selection criteria The source-literature selector kept SGLT2 inhibitors because the candidate bundle met the public source rule: 5 citable papers, 5 distinct fact-backed source identities, topic-overlapping source facts, and enough shared scope to compare metric/context disagreement. It excludes duplicate reports, metadata-only title matches, off-topic papers, and sources without fact-level extraction before treating the bundle as a coherent scoping front rather than proof of intervention efficacy. ## Plain-language synthesis Bounded signal: SGLT2 inhibitors is only a source-level context map; the selected receipts do not establish one pooled effect. ## Boundary map - SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis [review; 2023] doi:10.1038/s41598-023-42989-z - Finding: Use of an SGLT-2 inhibitor in patients with CKD was associated with a lower incidence of cardiovascular death (RR 0.87; 95% CI 0.79-0.95) - Population: patients with CKD (eGFR < 60 ml/min/1.73m²) - Intervention/exposure: SGLT-2 inhibitors - Comparator: placebo - Sodium‐Glucose Cotransporter‐2 Inhibitors After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Population‐Based Investigation [primary; 2023] doi:10.1161/jaha.122.027824 - Finding: the early use of SGLT2 inhibitors was associated with lower risks of the primary end point (HR 0.68 [95% CI, 0.54-0.87]; P=0.002) - Population: patients with type 2 diabetes and acute myocardial infarction undergoing percutaneous coronary intervention - Intervention/exposure: early use of SGLT2 inhibitors - Comparator: no use of SGLT2 inhibitors - Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis [review; 2022] doi:10.1186/s12933-022-01455-2 - Finding: Initiation of SGLT2 inhibitors in patients with AHF reduced the risk of rehospitalization for heart failure (OR 0.52; 95% CI [0.42, 0.65]) - Population: patients hospitalized with acute heart failure - Intervention/exposure: SGLT2 inhibitors initiation - Comparator: placebo - Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis [review; 2021] doi:10.1093/eurjpc/zwab173 - Finding: SGLT2i treatment significantly improved LV ejection fraction [SMD, 0.35; 95% CI (0.04, 0.65); P = 0.03] - Population: patients with type 2 diabetes mellitus and/or heart failure (13 RCTs, 1251 patients) - Intervention/exposure: sodium-glucose cotransporter-2 inhibitors (SGLT2i) - Comparator: control - SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies [review; 2021] doi:10.1016/j.phrs.2021.105836 - Finding: reduced risk of stroke with SGLT2 inhibitors compared to DPP-4 inhibitors (Hazard ratio HR, 0.89; 95%CI, 0.82-0.96) - Population: patients with type 2 diabetes mellitus - Intervention/exposure: SGLT2 inhibitors - Comparator: DPP-4 inhibitors ## Source synthesis Bounded signal: SGLT2 inhibitors is only a source-level context map; the selected receipts do not establish one pooled effect. ## Evidence matrix ### Effect-bearing comparison | Outcome family | Receipt | Evidence role | Population/setting | Metric | Extracted finding | |---|---|---|---|---|---| | outcome-specific | SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients... | directionally favorable | patients with CKD (eGFR < 60 ml/min/1.73m²) | - | Use of an SGLT-2 inhibitor in patients with CKD was associated with a lower incidence of cardiovascular death... | | outcome-specific | Sodium‐Glucose Cotransporter‐2 Inhibitors After Acute Myocardial... | directionally favorable | patients with type 2 diabetes and acute... | - | the early use of SGLT2 inhibitors was associated with lower risks of the primary end point (HR 0.68 [95% CI... | | outcome-specific | Efficacy and safety of sodium-glucose cotransporter 2 inhibitors... | directionally favorable | patients hospitalized with acute heart failure | - | Initiation of SGLT2 inhibitors in patients with AHF reduced the risk of rehospitalization for heart failure... | | outcome-specific | Effect of sodium-glucose cotransporter-2 inhibitors on cardiac... | directionally favorable | patients with type 2 diabetes mellitus and/or... | - | SGLT2i treatment significantly improved LV ejection fraction [SMD, 0.35; 95% CI (0.04, 0.65); P = 0.03] | | outcome-specific | SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular... | directionally favorable | patients with type 2 diabetes mellitus | - | reduced risk of stroke with SGLT2 inhibitors compared to DPP-4 inhibitors (Hazard ratio HR, 0.89; 95%CI... | This receipt-backed scoping note has one bounded signal: SGLT2 inhibitors shows directionally consistent signals across heterogeneous contexts across this 5-source primary/review bundle (2021-2023). Evidence role grouping: direction-bearing receipts: 5; null/mixed metric-scope caveat receipts: 0. The source facts cover 5 population/setting context(s) and 5 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. Direction is homogeneous: all selected receipts are directionally favorable. The boundary is population, comparator, and endpoint diversity, not directional disagreement. The listed effect sizes remain source-specific across endpoints and populations; they are not pooled or averaged. This is a heterogeneous indication/context map, not a unified disease-specific or endpoint-family claim. ## Directional grouping - directionally favorable: SGLT2 inhibitors is the intervention/exposure and the reported clinical endpoint favors that arm. - comparator/not favorable: SGLT2 inhibitors is the comparator arm; the label is limited to that head-to-head endpoint. - economic/context only: the receipt reports cost, QALY, or economic context rather than a clinical efficacy endpoint. - non-clinical/predictive: the receipt reports descriptive modelling, prediction, or age-clock performance rather than an intervention endpoint. - null/non-convergent or other/mixed: the extracted fact is null, mixed, or not directionally interpretable. - directionally favorable: SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis — Use of an SGLT-2 inhibitor in patients with CKD was associated with a lower incidence of cardiovascular death (RR 0.87; 95% CI 0.79-0.95) - directionally favorable: Sodium‐Glucose Cotransporter‐2 Inhibitors After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Population‐Based Investigation — the early use of SGLT2 inhibitors was associated with lower risks of the primary end point (HR 0.68 [95% CI, 0.54-0.87]; P=0.002) - directionally favorable: Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis — Initiation of SGLT2 inhibitors in patients with AHF reduced the risk of rehospitalization for heart failure (OR 0.52; 95% CI [0.42, 0.65]) - directionally favorable: Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis — SGLT2i treatment significantly improved LV ejection fraction [SMD, 0.35; 95% CI (0.04, 0.65); P = 0.03] - directionally favorable: SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies — reduced risk of stroke with SGLT2 inhibitors compared to DPP-4 inhibitors (Hazard ratio HR, 0.89; 95%CI, 0.82-0.96) Evidence role summary: direction-bearing receipts: 5; null/mixed metric-scope caveat receipts: 0. Direction labels for audit: directionally favorable: 5 receipt(s). Specific moderators in this bundle are population/indication (patients hospitalized with acute heart failure; patients with CKD (eGFR < 60 ml/min/1.73m²); patients with type 2 diabetes and acute myocardial infarction undergoing percutaneous coronary intervention; patients with type 2 diabetes mellitus; patients with type 2 diabetes mellitus and/or heart failure (13 RCTs, 1251 patients)), study design/evidence type (primary/review). Single primary-study estimates are separated from pooled review or meta-analytic estimates rather than treated as interchangeable. ## Context separation Population/settings are separated as receipt context: patients hospitalized with acute heart failure, patients with CKD (eGFR < 60 ml/min/1.73m²), patients with type 2 diabetes and acute myocardial infarction undergoing percutaneous coronary intervention, patients with type 2 diabetes mellitus, and patients with type 2 diabetes mellitus and/or heart failure (13 RCTs, 1251 patients). The selected receipts group because each carries a fact-level extraction for SGLT2 inhibitors; they separate by context (human clinical/observational) and endpoint, so they are not interchangeable evidence for one pooled claim. ## Boundary limits Source-literature boundary for SGLT2 inhibitors: the listed sources define one bounded, context-dependent signal across separate source contexts. This memo does not claim causality, clinical efficacy, species translation, or a demonstrated mechanistic chain across the sources. Material limitations: small 5-source bundle; no pooled estimate is possible; method/model receipts without direct effect estimates are context only; endpoints are not harmonized across studies. The signal is purely descriptive of source-level direction and scope; it cannot support even a weak causal or comparative-efficacy inference, and pooling across these PICOs would be inappropriate. Routing domain `longevity_research` is publication-lane metadata only; the source scope here is defined by the selected SGLT2 inhibitors receipts. ## What would weaken this - This scoping signal would weaken if a matched rerun finds five citable, fact-backed receipts in one population, intervention, and endpoint frame that remove the reported boundary, if the direction-bearing rows fail to reproduce within their named endpoint family, or if the context-only rows are the only topic-overlapping receipts. ## Next gaps A stronger memo needs one matched PICO: one population, one intervention/exposure, one comparator, and one named outcome. If SGLT2 inhibitors is promoted beyond a scoping note, the next run should select sources sharing one context family rather than spanning human clinical/observational.
metadata
{
"article_type": "alpha_memo",
"domain_slug": "longevity_research",
"researka_object_type": "submission",
"researka_submission_id": "8515943d-289a-4e78-9906-a7b91afe61b7",
"title": "SGLT2 inhibitors: one bounded, context-dependent signal across receipts"
}